| Prev Close | 21.15 |
| Day Low/High | 20.24 / 21.42 |
| 52 Wk Low/High | 20.12 / 58.72 |
ACADIA Pharmaceuticals Inc. (ACAD)
20.72
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 160.05B |
| Market Cap | 3.38B |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
My Takeaways and Observations (Early Edition)
I had my most active day of the year trading. It was also my most profitable. Regardless of one's market view, I continue to see more opportunities on the trading side vs. the investing side in the months ahead. I started the day with a story re...
My Takeaways and Observations
I have a series of meetings this afternoon and tomorrow morning so I want to get "Takeaways" out early today. I started with what I think is an important opening missive, "Wary in an Uncertain World" in which I covered a number of bases. I truly bel...
4 Biotech Names That Could Be M&A Targets
Animal health and oncology deal activity is heating up in 2017.
3 Biotechs Screaming 'Takeover Target'
M&A activity should perk up substantially in the small and mid-cap space this year.
My Takeaways and Observations
"Who you tryin' to get crazy with, 'ese? Don't you know I'm loco?..." -- Cypress Hill, Insane in the Brain 2017 will be the year of "The Dude." My favorite large-cap long Allergan and short Caterpillar for next year. AGN closed up by $4(!) wh...
My Takeaways and Observations
More of the same -- as Mr. Market remains enthusiastic with The Orange Swan and his contemplated policies aimed at catalyzing domestic economic growth. But, with fear and doubt having left Wall Street, we may be reaching The Outer Limits. And I ha...
Acadia Pharmaceuticals Soars After Positive Alzheimer's Disease Study
Shares of Acadia jumped Tuesday after the bio-pharmaceutical company reported positive results for a drug used for Alzehimer's patients.
My Takeaways and Observations
Slow day, at meetings all morning. Despite the strength in our currency (and its adverse implications on multi-national profitability), there was no follow-through to yesterday's schmeissing. I reflected on my July call that we have hit a Genera...
Takeaways and Observations
The markets moved lower from the "get go," though about the time Sixty Minutes was on last evening the S&P 500 futures were up 10 handles. (Futures closed down 2.5 handles) Perhaps this is the start of a well due correction. Apropos, here is the q...
My Takeaways and Observations
What a strange day -- maybe even ominous. This table tells it all. The divergences I have been mentioning this week intensified today, with the technology-laden Nasdaq taken out to the shed and the Russell 2000 Index trading lower for the third...
Biotech Hits an Inflection Point
The worst appears to be over for this sector; we could see big growth ahead.
The Good, the Bad and the Ugly
"If you work for a living, why the hell do you kill yourself working?" -- Tuco the Ugly" The Good, the Bad and the Ugly" I further added to my short exposure today in a quiet, pre-Thanksgiving trading session. And now it's time to run down "The Good...
The Good, the Bad and the Ugly (2:30 PM Edition)
"If you work for a living, why the hell do you kill yourself working?" -- Tuco the Ugly "The Good, the Bad and the Ugly" I did only a small amount of trading today (and added to short exposure), and there will be no "Takeaways" today (it's family ti...
4 Promising Small Biotechs to Watch in 2017
Veterinary drug play Aratana Therapeutics is among the potential solid performers next year.
2 Small-Cap Biotech Buyout Targets
With the election resolved, biotech could be ripe for consolidation.
My Takeaways and Observations (Early Edition)
I have been warning about weakening breadth and narrow leadership for weeks and months. What have we gotten? Eight straight days (in a row) down for the first time since 2008. But, with stocks suffering from election uncertainties and given the ...
Small Biotechs on My Shopping List
These small-caps are woefully undervalued after getting shellacked in October.
Main Biotech Indices Surrender Yesterday's Gains
It was good to stand in for Doug Kass today. Lots of lively conversation this Friday (over 200 comments), most of them around the markets as well....:-). The Daily Diary was certainly more interesting than today's market, which ended mixed as it clo...
Biotech Bargain Bin Bursts With Bounty
This sector is one of the few areas of the market where you'll find myriad compelling values.
The Good, the Bad and the Ugly
"You see, in this world there's two kinds of people, my friend: Those with loaded guns and those who dig. You dig." -- Blondie in "The Good, the Bad and the Ugly." I did very little today. Markets were higher from the get-go and seemed "stuck" nea...
My Takeaways and Observations
It was a nostalgic morning. A 20th anniversary. My first TST column in 1997. There was no rest for the weary as the crude and oil markets turned on a dime after OPEC announced a production cut. I, Jim Cramer and others are skeptical about this - s...
Biotechs Rally on Pfizer/Medivation Deal
The market is basically flat across the board to start the new week, but biotechs are strong overall in early going following news that Pfizer plans to buy Medivation for $14 billion. The sector's movers include some biotechs that I hold. For instan...
Bret Jensen Reporting for Duty
Good morning, Bret Jensen here! It's good to be standing in for Doug Kass again on the daily diary as we begin a new trading week. Biotech -- my favorite subject -- should be a hot topic today after Pfizer appears to have outbid Sanofi for oncology ...
Tracking Bullish and Bearish Reversals
These stocks have made U-turns in the past week.
Biowreck!
I warned in yesterday's Good, Bad and Ugly against taking shots on speculative stocks like biotech. Well, the biotech space is getting pummeled today. For example, Sage Therapeutics is down 11.8% as I write this, while Acadia Pharmaceuticals is off ...
It's 'All Systems Go' for Biotech
The sector seems to be rebounding after tumbling by more than 40%.
Investors Scour Big Pharma M&A Scene for Next Big Takeover
Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.
My Takeaways and Observations
Buyers live higher, sellers live lower. Markets are still Fed-centric and governed by the last lean by Yellen. Ali Ali Ali! Here's a very good column from El Capitan. Apple (AAPL) is Crapple (Part Deux) Fastenal (FAST) is always a good proxy for...
